Potassium Citrate

Identification

Name
Potassium Citrate
Accession Number
DB09125
Type
Small Molecule
Groups
Approved, Vet Approved
Description

Potassium citrate (also known as tripotassium citrate) is a potassium salt of citric acid. It is a white, hygroscopic crystalline powder. It is odorless with a saline taste. It contains 38.3% potassium by mass. In the monohydrate form it is highly hygroscopic and deliquescent. Potassium citrate is used to treat a kidney stone condition called renal tubular acidosis. Potassium Citrate is indicated also for the management of Hypocitraturic calcium oxalate nephrolithiasis.

Structure
Thumb
Synonyms
  • tripotassium citrate
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Potassium CitrateTablet15 meq/1OralBiocomp Pharma, Inc.2013-12-23Not applicableUs44523 0415 01 nlmimage10 4a3ea535
Potassium CitrateTablet5 meq/1OralUpsher Smith Laboratories, Llc2006-09-01Not applicableUs00245 0070 11 nlmimage10 234691d4
Potassium CitrateTablet10 meq/1OralUpsher Smith Laboratories, Llc2006-09-01Not applicableUs00245 0071 11 nlmimage10 f00df86f
Urocit KTablet, extended release540 mgOralMission Pharmacal1995-01-01Not applicableCanada
Urocit-KTablet, extended release10 meq/1OralRemedy Repack2016-12-27Not applicableUs
Urocit-KTablet, extended release10 meq/1OralMission Pharmacal1992-09-01Not applicableUs
Urocit-KTablet, extended release10 meq/1OralPhysicians Total Care, Inc.2003-04-17Not applicableUs
Urocit-KTablet, extended release1080 mgOralMission Pharmacal2011-02-11Not applicableCanada
Urocit-KTablet, extended release15 meq/1OralMission Pharmacal2010-01-27Not applicableUs
Urocit-KTablet, extended release15 meq/1OralPhysicians Total Care, Inc.2010-09-15Not applicableUs00178 0615 01 nlmimage10 581dac0d
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Potassium CitrateTablet, extended release1080 mg/1OralPhysicians Total Care, Inc.2006-07-24Not applicableUs
Potassium CitrateTablet, extended release15 meq/1OralCadila Pharnmaceuticals2014-08-12Not applicableUs
Potassium CitrateTablet, extended release10 meq/1OralZydus Pharmaceuticals Usa, Inc.2014-08-12Not applicableUs
Potassium CitrateTablet, extended release5 meq/1OralCadila Pharnmaceuticals2014-08-12Not applicableUs
Potassium CitrateTablet, extended release10 meq/1OralAmerincan Health Packaging2014-10-01Not applicableUs
Potassium CitrateTablet, extended release15 meq/1OralZydus Pharmaceuticals Usa, Inc.2014-08-12Not applicableUs
Potassium CitrateTablet, extended release10 meq/1OralCadila Pharnmaceuticals2014-08-12Not applicableUs
Potassium CitrateTablet, extended release5 meq/1OralZydus Pharmaceuticals Usa, Inc.2014-08-12Not applicableUs
Potassium Citrate Extended ReleaseTablet5 meq/1OralVensun Pharmaceuticals, Inc.2016-07-07Not applicableUs
Potassium Citrate Extended ReleaseTablet10 meq/1OralVensun Pharmaceuticals, Inc.2016-07-07Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
B6 Plus TabPotassium Citrate (50 mg) + Magnesium oxide (50 mg) + Niacin (20 mg) + Pyridoxine hydrochloride (50 mg) + Riboflavin (2.4 mg) + Thiamine (10 mg)TabletOralVita Health Products Inc1979-12-312002-08-01Canada
Cytra-K CrystalsPotassium Citrate (3.3 g/1) + Citric acid monohydrate (1.002 g/1)Granule, for solutionOralCypress Pharmaceuticals, Inc.2003-05-01Not applicableUs
Formula No. 2 Plus K LiqPotassium Citrate (19.5 mg) + Vitamin C (2 mg)LiquidOralGolden Pride/Rawleigh1993-12-311996-09-30Canada
LytrenPotassium Citrate (270 mg) + Citric Acid (26 mg) + Glucose (2 g) + Sodium Chloride (263 mg) + Sodium Citrate (49 mg)LiquidOralMead Johnson Nutritionals1985-12-312003-07-08Canada
Lytren Rhs LiqPotassium Citrate (217 mg) + Citric Acid (26.1 mg) + Sodium Chloride (375 mg) + Sodium Citrate (107 mg)LiquidOralMead Johnson Nutritionals1990-12-312000-09-11Canada
Potassium Citrate and Citric AcidPotassium Citrate (1100 mg/5mL) + Citric acid monohydrate (334 mg/5mL)SolutionOralPharmaceutical Associates, Inc.1997-10-07Not applicableUs
Potassium Citrate Citric Acid CrystalsPotassium Citrate (3.3 g/1) + Citric acid monohydrate (1.002 g/1)Granule, for solutionOralVirtus Pharmaceuticals2014-06-13Not applicableUs
Potassium Citrate-Citric AcidPotassium Citrate (1100 mg/5mL) + Citric acid monohydrate (334 mg/5mL)SolutionOralMethod Pharmaceuticals2015-12-212016-03-05Us
Potassium Citrate-Citric AcidPotassium Citrate (1100 mg/5mL) + Citric acid monohydrate (334 mg/5mL)SolutionOralMethod Pharmaceuticals2014-10-202015-12-31Us
Potassium Citrate-Sodium Citrate-Citric AcidPotassium Citrate (550 mg/5mL) + Citric acid monohydrate (334 mg/5mL) + Trisodium citrate dihydrate (500 mg/5mL)SolutionOralMethod Pharmaceuticals2015-12-212016-03-05Us
Categories
UNII
86R1NVR0HW
CAS number
Not Available
Weight
Average: 306.394
Monoisotopic: 305.89464697
Chemical Formula
C6H5K3O7
InChI Key
QEEAPRPFLLJWCF-UHFFFAOYSA-K
InChI
InChI=1S/C6H8O7.3K/c7-3(8)1-6(13,5(11)12)2-4(9)10;;;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;/q;3*+1/p-3
IUPAC Name
tripotassium 2-hydroxypropane-1,2,3-tricarboxylate
SMILES
[K+].[K+].[K+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O

Pharmacology

Indication

For the management of renal tubular acidosis, hypocitraturic calcium oxalate nephrolithiasis, and uric acid lithiasis with or without calcium stones.

Structured Indications
Pharmacodynamics

Potassium citrate induces changes in the urine which renders urine less susceptible to the formation of crystals and stones from salts e.g. calcium oxalate, calcium phosphate and uric acid. Increased citrate levels in the urine will make complexation with calcium which decrease the calcium ion activity and decrease the chance for the formation of calcium phosphate crystals. Citrate also inhibits the spontaneous nucleation of calcium oxalate and calcium phosphate.

Mechanism of action

After oral administration of potassium citrate, its metabolism yields alkaline load. Potassium Citrate therapy appears to increase urinary citrate mainly by modifying the renal handling of citrate, rather than by increasing the filtered load of citrate. In addition to raising urinary pH and citrate, Potassium Citrate increases urinary potassium by approximately the amount contained in the medication. In some patients, Potassium Citrate causes a transient reduction in urinary calcium.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Potassium Citrate is absorbed and the citrate is metabolised to bicarbonate.

Route of elimination

Urinary; less than 5% unchanged.

Half life
Not Available
Clearance
Not Available
Toxicity

LD50 (dog): Intravenous 176 mg/kg.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Potassium Citrate.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Potassium Citrate.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Potassium Citrate.Illicit
Aluminum hydroxidePotassium Citrate can cause an increase in the absorption of Aluminum hydroxide resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Potassium Citrate.Experimental, Illicit, Withdrawn
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Potassium Citrate.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Potassium Citrate.Approved, Illicit, Vet Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Potassium Citrate.Illicit, Vet Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Potassium Citrate.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Potassium Citrate.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Potassium Citrate.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Potassium Citrate.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Potassium Citrate.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Potassium Citrate.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Potassium Citrate.Experimental, Illicit
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Potassium Citrate.Approved, Illicit
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Potassium Citrate.Investigational
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Potassium Citrate.Approved, Illicit
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Potassium Citrate.Illicit, Vet Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Potassium Citrate.Approved, Illicit, Investigational, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Potassium Citrate.Approved, Illicit
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Potassium Citrate.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Potassium Citrate.Approved, Illicit
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Potassium Citrate.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Potassium Citrate.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Potassium Citrate.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Potassium Citrate.Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Potassium Citrate.Experimental
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Potassium Citrate.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Potassium Citrate.Approved, Illicit
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Potassium Citrate.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Potassium Citrate.Approved
NicomorphineThe risk or severity of adverse effects can be increased when Nicomorphine is combined with Potassium Citrate.Experimental
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Potassium Citrate.Approved, Illicit
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Potassium Citrate.Approved, Illicit
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Potassium Citrate.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Potassium Citrate.Approved, Investigational, Vet Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Potassium Citrate.Approved, Vet Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Potassium Citrate.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Potassium Citrate.Experimental
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Potassium Citrate.Experimental
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Potassium Citrate.Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Potassium Citrate.Approved
Sodium phosphatePotassium Citrate may increase the nephrotoxic activities of Sodium phosphate.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Potassium Citrate.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Potassium Citrate.Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Potassium Citrate.Experimental
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Potassium Citrate.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Monograph [Link]
  2. safety data sheet [Link]
External Links
PubChem Compound
13344
PubChem Substance
310265041
ChemSpider
12775
ChEBI
64733
ChEMBL
CHEMBL1200458
Wikipedia
Potassium_citrate
ATC Codes
A12BA02 — Potassium citrate
AHFS Codes
  • 40:12.00 — Replacement Preparations
FDA label
Download (81.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentBone Diseases / Metabolic Acidosis / Mineral Metabolism / Physical Capacity / Renal Transplant Patients1
3CompletedTreatmentHealthy Volunteers1
3CompletedTreatmentHypercalciuria / Renal Stones1
3Unknown StatusPreventionNephrocalcinosis1
4RecruitingTreatmentRenal Stones / Urolithiasis1
4Unknown StatusTreatmentBone Diseases, Metabolic / Postmenopausal Osteoporosis (PMO)1
Not AvailableCompletedDiagnosticRenal Stones1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral
LiquidOral
TabletOral15 meq/1
Tablet, extended releaseOral1080 mg/1
Tablet, extended releaseOral5 meq/1
Granule, for solutionOral
TabletOral10 meq/1
TabletOral5 meq/1
SolutionOral
Tablet, extended releaseOral540 mg
Tablet, extended releaseOral10 meq/1
Tablet, extended releaseOral1080 mg
Tablet, extended releaseOral15 meq/1
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility39.4 mg/mLALOGPS
logP-0.7ALOGPS
logP-1.3ChemAxon
logS-0.89ALOGPS
pKa (Strongest Acidic)3.05ChemAxon
pKa (Strongest Basic)-4.2ChemAxon
Physiological Charge-3ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area140.62 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity68.14 m3·mol-1ChemAxon
Polarizability14.23 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as tricarboxylic acids and derivatives. These are carboxylic acids containing exactly three carboxyl groups.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Tricarboxylic acids and derivatives
Direct Parent
Tricarboxylic acids and derivatives
Alternative Parents
Tertiary alcohols / Carboxylic acid salts / Carboxylic acids / Organic potassium salts / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Tricarboxylic acid or derivatives / Tertiary alcohol / Carboxylic acid salt / Organic alkali metal salt / Carboxylic acid / Organic oxygen compound / Organic oxide / Hydrocarbon derivative / Organic potassium salt / Organic salt
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
potassium salt (CHEBI:64733)

Drug created on September 23, 2015 10:41 / Updated on October 23, 2017 14:13